Navigation Links
Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
Date:3/28/2008

o fast-scan cyclic voltammetry in anesthetized rats. A stimulation train was delivered to the ventral tegmental area every five minutes and the resultant dopamine and rate of reuptake were measured. Peak concentrations of dopamine and the rate of dopamine reuptake were monitored in response to intraperitoneal injections of MSI-1436, saline or nomafensine (a known inhibitor of DAT). Post-hoc analyses indicated that the peak dopamine concentration and the rate of dopamine reuptake (tau) significantly increased from baseline only after injection with nomifensine and that neither MSI-1436 nor the saline control had an effect on these measurements.

"These studies serve to further confirm the selectivity of MSI-1436 as an inhibitor of PTP-1B and addresses one of the critical issues involved in the development of anti-obesity drugs," states Jack Armstrong, President and Chief Executive Officer of Genaera. "The low addictive potential of MSI-1436 further differentiates it from many other drug candidates in development. While MSI- 1436 is being developed to treat both type 2 diabetes and obesity, we believe it is essential to demonstrate that the side effects seen in other weight-loss only drugs are not observed with MSI-1436. We continue to differentiate MSI- 1436 from other drugs for anti-obesity and anti-diabetes indications through our preclinical studies and look forward to reporting additional supportive clinical data later this year."

The researchers included Dr. Roitman and Seth A. Wescott from the University of Illinois at Chicago, as well as Michael P. McLane, Ph.D. and Henry R. Wolfe, Ph.D. from Genaera.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 tria
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 InfuSystem Holdings, Inc. ... and related services for the healthcare industry in ... , announced today it has secured a new $45.0 million ... its previous $36.5 million credit facility with its prior lender ... entered into the new five-year senior secured credit agreement comprised ...
(Date:3/26/2015)... , 26. März 2015  Die National ... vom 1. April 2015 an Zulassungsanträge für Domainnamen ... Apotheken annehmen. Seit dem Start des .Pharmacy ... über 275 .pharmacy-Domainnamen zugelassen, die für die ... beantragt wurden. Die NABP startete .pharmacy TLD, ...
(Date:3/26/2015)... Editor Note: For more information about ... Investor-Edge has initiated coverage on the following equities: Mylan ... SLXP ), Hospira Inc. (NYSE: HSP ), ... (NASDAQ: AKRX ). Free research report on Mylan ... markets declined on Wednesday, March 25, 2015, as the ...
Breaking Medicine Technology:InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 2Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 3Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 4Active Equities to Watch in the Pharma Industry -- Mylan, Salix Pharma, Hospira, VIVUS, and Akorn 5
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... company completed its previously announced acquisition of AB Sanitas ... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ... and markets a broad range of pharmaceutical products primarily ...
... Medical Inc. (NYSE: SMA ), a leading ... implants, surgical instruments, and sterilization cases and trays, announced ... of Olsen Medical. Olsen Medical is a ... of electrosurgical instruments and accessories. It manufactures a full ...
Cached Medicine Technology:Symmetry Medical Closes Olsen Medical Acquisition 2
(Date:3/26/2015)... New York (PRWEB) March 26, 2015 ... to move forward nationwide, with the issuance of ... in Pennsylvania and Louisiana. According to an Order ... multidistrict litigation established for Xarelto injury claims in ... will now allow plaintiffs to file cases directly ...
(Date:3/26/2015)... 2015 “The SWEET Act is an important ... more available and help parents who are working to reduce ... reasonable approach to support public health, and we will continue ... the health of all families,” said Dr. Jane Delgado President ... the introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by ...
(Date:3/26/2015)... Frencisco, CA (PRWEB) March 26, 2015 ... Center are proud to announce expanded offerings for Bay ... San Francisco Dental Implant Center has long been a ... have expanded its offerings to meet the strong demand ... in our reputation as a top-rated dental implant facility ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... In the key developed markets, the hypertension market ... set to decrease through 2020 at a negative CAGR (0.9%) ... up to 2017 at a 2.6% CAGR and a decline ... the surging penetration of fixed-dose combination drugs like Azor, Amturnide, ... HCT, and Tekamlo), a hike in the prevalence population to ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... FRIDAY, July 8 (HealthDay News) -- Obese people who ... to suffer from complications than those of normal weight, ... are often used by insurance companies, the Johns Hopkins ... and hospitals are reimbursed for more complex procedures or ...
... As any student who,s had to study for multiple exams ... facts one after another is challenging. As you study for ... the history exam is forgotten. It,s been widely believed that ... have the capacity necessary to process both memories in quick ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... threatens America,s future reveals that obesity rates climbed over the ... reported a decline in the proportion of excessively overweight residents. ... 30 percent of the people in 12 states are obese. ...
... analysis of heart disease and stroke statistics collected in 192 ... relative burden of the two diseases varies widely from country ... to researchers at the University of California, San Francisco. ... UCSF scientists found that developing countries tend to suffer more ...
... at the Neglected Tropical Diseases Meeting of the International ... for Neglected Diseases initiative (DNDi) announced the first research ... portfolio to address unmet needs of patients in Africa ... potential of the drug flubendazole to treat a highly ...
... (HealthDay News) -- It is well-known that smoking is unhealthy, ... require total hip or knee replacement, according to a new ... doing vigorous physical activity increased the likelihood of joint replacement. ... of 11,388 men who were followed from 1996-1999 to March ...
Cached Medicine News:Health News:Obesity May Increase Risk of Surgical Complications 2Health News:Study demonstrates how memory can be preserved -- and forgetting prevented 2Health News:U.S. Obesity Epidemic Continues to Spread 2Health News:U.S. Obesity Epidemic Continues to Spread 3Health News:Heart disease and stroke worldwide tied to national income 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 3Health News:Men Who Smoke at Lower Risk of Joint Replacement: Study 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
Medicine Products: